In anticancer chemotherapy, drug targeting and delivery methods depend on agents with selective access to cancer cells to deliver drugs to the target, and approaches to finding such agents often depend on novel design strategies employing bioactive vectors. Platinum-based complexes are extremely important drugs for the treatment of cancer. Recently synthesized complexes of Pt (IV) have been shown to have several advantages, such as they are safer, can be used orally, are highly anti-cancer effective, there is no cross-resistance to cisplatin, and their effectiveness is compared with commonly used Pt (II) compounds such as cisplatin and oxaliplatin. A molecular mimicry model for the generation of new active drugs may be synthesized by the 3,5-ditert-butyl-2-hydroxy-benzylaminocysteine (DTHBAC) where a cysteine group and two tertiary butyl groups attached to the phenol aromatic ring can be coordinated with platinum. This appropriate ligand with the platinum complex is fit for the anticancer drug. Based on the present modeling, it can be recommended in the management of patients, and from this perspective, the status of the platinum anticancer drug field will develop over the next decade. Moreover, the authors have no doubt that this will benefit patients in the future and will be widely used in cancer treatment for years to come.